On October 28, 2026, the Department of Health and Human Services published a draft interim enforcement discretion policy in the Federal Register covering six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy states that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound with them under section 503A of the FD&C Act, provided ten conditions are met. The FDA's Pharmacy Compounding Advisory Committee voted in July in favor of adding these six peptides to the 503A Bulks List. This draft does not add them. It binds neither HHS nor the public, and it creates no rights. Several telehealth platforms already advertise peptide offerings starting at $109 per month.

But the same document that lets a licensed pharmacy compound BPC-157 leaves an athlete's sample cup exactly where the World Anti-Doping Agency put it. A physician's prescription does not function as a therapeutic use exemption, and the two documents were never written to reference each other. An athlete can still be banned. HHS enforcement discretion binds HHS enforcement alone. It does not bind WADA, the US Anti-Doping Agency or the tribunal that hears the case.
WADA's list governs the sample cup, not the pharmacy

WADA's Prohibited List governs what an athlete may have in their body in and out of competition. BPC-157 and TB-500 remain prohibited under the anti-doping rules used by many tested sports. A change in how federal regulators treat compounding leaves that list untouched. The lawful route for a prohibited substance is a therapeutic use exemption, granted through a formal process before use, on specific medical criteria. A section 503A prescription is a different instrument, and its legal force ends at the pharmacy counter.
The compliance burden has moved. Before this draft, an athlete seeking a peptide had to find a source the FDA had not vetted. Now the athlete can find a licensed pharmacy and a licensed prescriber, and the sanction risk remains in the anti-doping rules the federal paperwork never touched.

Enforcement discretion is interim, conditional and reversible
The policy is expressly interim. It applies until each peptide is addressed in a final rule that includes or excludes it from the 503A bulks list, and HHS may revisit it in whole or in part if a safety signal or product quality problem emerges. The notice does not add the six peptides to the bulks list, and it leaves section 503A compliance unchanged. The text itself describes an unusual departure from CDER recommendations against listing these peptides, achieved through conditional forbearance rather than rulemaking.
The policy was issued by the HHS Office of the Secretary and signed by Secretary Robert F. Kennedy Jr., not by the FDA, which administers section 503A. Holland & Knight notes that FDA scientific reviewers had recommended against adding these peptides, and the policy creates an access pathway regardless.
The ten conditions are demanding. They cover route-of-administration limits, certificate-of-analysis and supplier-registration requirements, MedWatch adverse-event reporting, single-ingredient products, required labeling and a syringe-only device limit. Those conditions may exceed what some pharmacies can verify in sourcing and reporting today. The policy does not extend to 503B outsourcing facilities and does not change the status of research-use-only peptides. It also does not bind state regulators. State attorneys general are signaling increased enforcement against deceptive marketing of these products, and private plaintiffs may still bring state-law claims.
What the record confirms and what it leaves open
The confirmed core is narrow: the six substances, the ten conditions, the interim scope, the no-rights language, the Secretary-level signature, the departure from CDER and the July committee vote. Coverage disagrees on the publication date, with several firms citing October 28 as the Federal Register date and October 30 as the date the announcement became available. Neither date changes the substance.
The reported but unsettled material matters more. FDA scientists raised concerns about thin clinical data and product safety, while the advisory committee's vote points the other way. Human evidence for the broad claims made about BPC-157 and TB-500 is thin. A cleaner supply chain does not establish that a molecule works. Compounded drugs are not FDA-approved, so the agency does not review their safety, effectiveness or quality before they reach patients. Anyone describing this as FDA approval has misread the document.
HHS's stated rationale is coherent on its own terms. The agency says the policy aims to discourage widespread use of research-use-only peptides from foreign manufacturers that pose safety risks, and to give patients a more controlled alternative. It frames the policy as advancing patient choice and freedom while protecting safety. Those goals belong to a regulatory conversation separate from the one WADA is having.
The first banned athlete with a valid prescription is likely within 12 to 24 months
The prediction is stated so it can be checked. Within 12 to 24 months, a tested athlete sanctioned for a peptide obtained through a compliant 503A prescription is likely to surface. The case will read as a documentation problem: a valid prescription, a compliant pharmacy, a licensed physician and a positive sample. The sanction will rest on anti-doping rules the HHS draft cannot reach. The prediction fails if no such case surfaces within that window, or if WADA amends its rules to recognize section 503A prescriptions.
The mechanism is structural. Two federal-adjacent regimes now describe the same molecule in incompatible terms. HHS is extending forbearance on the supply side, while WADA maintains prohibition on the athlete side. No mechanism reconciles them, and the athlete is the only party bound by both. Compliant pharmacies and telehealth platforms can market physician-supervised access at $109 a month while disclaiming sports use. That marketing is permitted under the HHS draft, and it sends a competing customer into a system that does not treat the prescription as a defense.
The pharmacies and platforms that monetize access inside the forbearance window gain. Athletes who read the HHS release and the WADA list as the same government speaking lose, along with any pharmacy that markets to athletic populations and draws a state attorney general's attention. The durable effect is two regimes describing one molecule in different languages, with the athlete left to translate.
The compliance burden lands on the sample cup
The burden has moved away from the agencies that wrote the draft and toward the person least able to misread it. An athlete who once needed a source now needs documentation, proof of intent and an understanding of a tribunal that does not recognize HHS forbearance. The telehealth customer receives a prescription that is medically valid and irrelevant to sport. The prescribing physician faces no HHS enforcement and nothing the anti-doping system cares about.
The patient-choice rationale and the anti-doping rationale are both internally coherent and mutually blind. HHS can accurately say it is not pursuing enforcement. WADA can accurately say the substance is prohibited. Neither statement contradicts the other, and that gap is where the athlete is exposed.
The draft moved the risk without removing it
On October 28, a draft notice in the Federal Register opened a federal enforcement pathway for six peptides, and several platforms began selling access from $109 a month. The notice did not legalize those peptides, did not make them compliant with section 503A and did not touch the WADA rulebook. It relocated the compliance risk from the FDA to the athlete's sample cup. The first athlete to discover the difference will be one holding a legitimate prescription and facing a ban.